Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis

Journal of Cardiovascular Pharmacology
Shaker A MousaKonstantinos Konstantopoulos

Abstract

This study was undertaken to compare the platelet binding characteristics and anti-platelet efficacy of a nonpeptide glycoprotein IIb/IIIa antagonist roxifiban with orbofiban in static and dynamic adhesion and aggregation assays. The results indicate that roxifiban binds with higher affinity to glycoprotein IIb/IIIa receptors and exhibits slower dissociation rates than orbofiban. Furthermore, the platelet inhibitory effects of roxifiban, but not orbofiban, were unaffected by changes in plasma calcium concentrations. Both agents reduced, in a concentration-dependent manner, the size of platelet thrombi deposited onto collagen I upon perfusion of heparinized blood at a shear rate of 1,500/s. At a clinically achievable concentration of 60 nM, roxifiban abrogated the formation of thrombi containing > 20 platelets per thrombus, thereby displaying comparable in vitro efficacy to that achieved by the theoretical maximal abciximab blood concentration (3.5 microg/ml) produced after standard treatment. In contrast, orbofiban, even at 500 nM, was only effective in inhibiting the formation of larger platelet thrombi (> or =150 platelets per thrombus). Pretreatment of surface-anchored platelets with roxifiban (100 nM), but not orbofiban (50...Continue Reading

References

Oct 16, 1986·The New England Journal of Medicine·D J FitzgeraldG A FitzGerald
Feb 1, 1997·Journal of Cardiovascular Pharmacology·S G KamatJ L Moake
Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
Aug 15, 1998·The New England Journal of Medicine·UNKNOWN Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigato
Jun 6, 2000·Advanced Drug Delivery Reviews·K KonstantopoulosL V McIntire
Jan 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·J P AbulenciaK Konstantopoulos

❮ Previous
Next ❯

Citations

Feb 1, 2008·American Journal of Physiology. Cell Physiology·Christina S AlvesKonstantinos Konstantopoulos
Jan 17, 2003·American Journal of Physiology. Cell Physiology·Owen J T McCartyKonstantinos Konstantopoulos
Jan 14, 2017·Cellular and Molecular Bioengineering·Jevgenia Zilberman-RudenkoOwen J T McCarty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.